

Table S1 Previous chemotherapy regimens of patients in second-line and third-line or beyond treatment of apatinib

Regimens of prior anticancer therapies	Number (%)
Apatinib as second-line or beyond treatment (N=57)	
First-line regimens	
Etoposide and platinum	44 (77.2)
Irinotecan and platinum	6 (10.5)
Other	3 (5.3)
Missing	5 (8.8)
Apatinib as third-line or beyond treatment (N=27)	
Second-line regimens	
Irinotecan-based	
Irinotecan	3 (11.1)
Irinotecan and platinum	15 (55.6)
Etoposide and platinum	3 (11.1)
Taxane-based	
Taxane	1 (3.7)
Taxane and platinum	1 (3.7)
Missing	4 (14.8)




Figure S1 The comparison of median progression-free survival (PFS) and/or median overall survival (OS) of the clinical trials on the second- or beyond-chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients.